BiotechTube

RO7234292 (RG6042)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Apr 23, 2019 → Mar 30, 2022

NCT ID
NCT03842969

About RO7234292 (RG6042)

RO7234292 (RG6042) is a phase 3 stage product being developed by Roche for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03842969. Target conditions include Huntington Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT04000594Phase 1Completed
NCT03842969Phase 3Completed
NCT03342053Phase 2Completed

Competing Products

20 competing products in Huntington Disease

See all competitors
ProductCompanyStageHype Score
atomoxetine + Matching PlaceboEli LillyPhase 2
52
Votoplam (blinded) + PlaceboNovartisPhase 3
77
VotoplamNovartisPhase 2
52
Branaplam + PlaceboNovartisPhase 2
52
AFQ056 + PlaceboNovartisPhase 2
52
RO7234292 (RG6042)RochePhase 1
33
Tominersen + PlaceboRochePhase 2
52
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
RO7234292 + PlaceboRochePhase 3
77
PF-02545920 + PF-02545920PfizerPhase 2
51
Dextromethorphan + Dimebon + DextromethorphanPfizerPhase 1
32
DimebonPfizerPhase 3
76
Dimebon (latrepirdine)PfizerPhase 3
76
20 mg BID of PF-02545920PfizerPhase 2
51
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
51
RiluzoleSanofiPhase 3
76
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
TetrabenazineLundbeckApproved
82
ValbenazineNeurocrine BiosciencesPhase 3
74

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85